




#4 1648
lw

PATENT
Attorney Docket No.: 27373/37922

TECH CENTER 1600/2900

APR 17 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Schwartz, L.B. et al.)	I hereby certify that this paper is being
)	deposited with the United States Postal
Serial No.: 09/995,475)	Service with sufficient postage as first
)	class mail in an envelope addressed to:
Filed: November 28, 2001)	Commissioner for Patents, Washington,
)	D.C. 20231 on this date:
For: Genetically Engineered)	
Herpes Virus For The Treatment Of)	April 12, 2002
Cardiovascular Disease)	
)	
Group Art Unit: To be assigned)	Thomas A. Cawley, Jr.
)	Registration No. 40,944
Examiner: To be assigned)	Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with 37 C.F.R. §1.97 and the continuing duty of disclosure under 37 C.F.R. §1.56, the applicants call to the attention of the examiner the publications, listed on the attached Form PTO-1449, which may be considered material to the examination of the above-identified patent application.


This statement and the accompanying items of information, including a Form PTO-1449, are being submitted before receipt of a first official action in the above-identified patent application. Accordingly, it is submitted that no fee is due in this matter under 37 C.F.R. §1.97(b). However, if it is determined that any appropriate fee is due, the Commissioner is hereby authorized to charge deposit account no. 13-2855.

An early and favorable action on the merits is solicited.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300

By:



Thomas A. Cawley, Jr.
Reg. No: 40,944

April 12, 2002